Skip to content Skip to footer
Subscribe Now

INSIGHTS+

Top Performing Drug – Xtandi (December Edition)
Top Performing Drug – Xtandi (December Edition)
Shots:   In continuation of our previous series on the Top-Performing Drug of the month, based on 2021 revenue, this month we have selected Xtandi and prepared a curated analysis report for our readers  Xtandi is indicated for the treatment of certain prostate cancers  PharmaShots presents a concise take on the key features of Xtandi with…
December 28, 2023
New Drug Designations - November 2023
New Drug Designations – November 2023
Shots:  PharmaShots' designation report provides a concise overview of several drugs and their designations by the US FDA, EMA and China. This month’s report includes 3 biological drugs, 12 small molecules, 13 cell and gene therapies, 1 peptide, 3 exosome-based therapy and 4 devices  Atsena Therapeutics’ capsid AAV.SPR gene therapy, focused on the treatment of Leber congenital…
December 27, 2023
Know Your Investor: Google Ventures
Know Your Investor: Google Ventures
Shots:  An investment arm of Alphabet Inc., Google Ventures Management Company colossally in seed stage companies, in diverse fields ranging from software and internet to healthcare, life sciences, and artificial intelligence among others  Since 2016, GV has shifted its focus from seed-stage companies to evolved companies. With over $8B worth of assets under the management…
December 27, 2023
Insights+: The US FDA New Drug Approvals in November 2023
Insights+: The US FDA New Drug Approvals in November 2023 
Shots:  The US FDA approved 5 NDAs & 4 BLAs in November 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 109 novel products in 2023  In November 2023, the major highlights drugs were Wezlana (ustekinumab) approved for Multiple Inflammatory Diseases, and Cosentyx (secukinumab) for the Treatment…
December 20, 2023
Disease of the Month - Pancreatic Cancer
Disease of the Month – Pancreatic Cancer
Shots To keep our readers acquainted with several disease conditions, ongoing trials, and available treatment options, PharmaShots brings every month a detailed take on a particular disease after thorough research   Continuing the series for the Disease of the Month, PharmaShots brings a condensed report on Pancreatic Cancer  November 16th is observed as World Pancreatic Cancer…
December 18, 2023
Insights+ Key Biosimilars Events of November 2023
Insights+ Key Biosimilars Events of November 2023
Shots: Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency   Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients   During November, Amgen received US FDA approval for Wezlana, biosimilar of ustekinumab &…
December 6, 2023
Know Your Investor: Alexandria Venture Investments
Know Your Investor: Alexandria Venture Investments
Shots: Know Your Investor’s November Edition revolves around Alexandria Venture Investments, which dedicatedly invests in the healthcare sector  Established in 1996, Alexandria Venture Investments is based in Pasadena, California, and is the corporate venture capital arm of Alexandria Real Estate Equities In 2022, Alexandria participated in 31 investment rounds, with Affini-T Therapeutics receiving the highest…
November 29, 2023
Disease of the Month - Ulcerative Colitis
Disease of the Month – Ulcerative Colitis
Shots:  To keep our readers acquainted with several disease conditions, ongoing trials, and available treatment options, PharmaShots brings every month a detailed take on a particular disease after thorough research   Continuing the series for the disease of the month, PharmaShots presents a condensed report on Ulcerative Colitis, which causes inflammation and sores (ulcers) in the digestive…
November 28, 2023
Insights+: EMA Marketing Authorization of New Drugs in October 2023
Insights+: EMA Marketing Authorization of New Drugs in October 2023
Shots: The EMA approved 2 BLA while 7 new chemical Entity, 6 BLA received positive CHMP opinion in October 2023, leading to treatments for patients and advances in the healthcare industry In October 2023, the major highlight drugs were Keytruda + trastuzumab 1L treatment of LA unresectable or metastatic HER2+ gastric or GEJ adenocarcinoma &…
November 23, 2023
Top Performing Drug – Cosentyx (November Edition)
Top Performing Drug – Cosentyx (November Edition)
Shots:   In continuation of our previous series on the Top-Performing Drug of the month, based on 2021 revenue, this month we have selected Cosentyx and prepared a curated analysis report for our readers  Cosentyx is indicated for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. It is a human IgG1κ mAb which targets interleukin (IL)-17A    PharmaShots presents a…
November 22, 2023
Load more